Tag: anti-BCMA

Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

TOPLINE: Belantamab mafodotin plus a combination of bortezomib and dexamethasone improved median progression-free survival (PFS) by 23 months in patients with relapsed or refractory multiple myeloma compared with daratumumab alongside the same combination. METHODOLOGY: Belantamab mafodotin, a first-in-class anti-BCMA monoclonal antibody conjugate, was approved in the US in 2020 for…

Continue Reading Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

[PDF] A Scalable, Off-the-Shelf, and Cost-Effective NK Cell Manufacturing Platform for Developing NK Cell-Based Immunotherapy

Natural killer (NK) cells are innate lymphocytes that play a key role in the control of infection and malignancy. NK cells are potent killers of target cells and act in an MHC-independent manner, enabling their application as allogenic therapy for cancer. Human iPSCs are pluripotent with the ability to self-renew,…

Continue Reading [PDF] A Scalable, Off-the-Shelf, and Cost-Effective NK Cell Manufacturing Platform for Developing NK Cell-Based Immunotherapy

Singleron Biotechnologies announces two co-authored abstracts at the American Society of Hematology conference

Using single cell multi-omics analysis to predict treatment outcome, develop disease prognostics and track patient responses to CAR T therapies COLOGNE, Germany, Nov. 17, 2023 /PRNewswire/ — Singleron Biotechnologies, a company at the forefront of developing and commercializing innovative single cell multi-omic analysis solutions for precision medicine, has announced two…

Continue Reading Singleron Biotechnologies announces two co-authored abstracts at the American Society of Hematology conference

Celyad Oncology reports third quarter 2023 financial

Publication of data detailing the development of our microRNA (miRNA)-based multiplex shRNA approach, which allows to down-regulate several genes simultaneously, in Molecular Therapy – Nucleic Acids Five posters were presented at the 38th SITC Annual Meeting and two posters were presented at the 4th ICLE conference, with further developments in…

Continue Reading Celyad Oncology reports third quarter 2023 financial

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

Caribou Biosciences, Inc. — Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma — BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) —  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory…

Continue Reading Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

Mutations in Target Proteins Provide Fresh View of Multiple Myeloma Resistance to T-Cell Therapies

NEW YORK – Newly identified genomic alterations associated with relapse and resistance to targeted T-cell therapies in multiple myeloma patients may offer opportunities for tailoring treatment, according to a study published Thursday in Nature Medicine.  A group of researchers from City of Hope, the University of Miami, the University of…

Continue Reading Mutations in Target Proteins Provide Fresh View of Multiple Myeloma Resistance to T-Cell Therapies

Caribou Biosciences Announces $25 Million Equity Investment

— Pfizer purchases $25 million of Caribou common shares — — Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou’s Scientific Advisory Board — BERKELEY, Calif., July 06, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing…

Continue Reading Caribou Biosciences Announces $25 Million Equity Investment

Kelonia shows data for transformative multiple myeloma treatment

Kelonia Therapeutics, a biotech company working on in vivo gene delivery, has announced the results of preclinical research demonstrating that its in vivo Gene Placement System (iGPS) technology efficiently delivered CAR molecules specifically to T cells at therapeutic dose levels in both mice and non-human primates (NHPs).  Kelonia’s iGPS platform…

Continue Reading Kelonia shows data for transformative multiple myeloma treatment

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board — Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development — BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today…

Continue Reading Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, NDA Approvals, and Emerging Therapies| Key Companies- Novartis, Janssen Pharmaceuticals, and Others

PRESS RELEASE Published May 5, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in the Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor…

Continue Reading Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, NDA Approvals, and Emerging Therapies| Key Companies- Novartis, Janssen Pharmaceuticals, and Others

FDA Accepts sBLA for Ide-cel in Triple-class Exposed Relapsed/Refractory Myeloma

The FDA has accepted a supplemental biologics license application (sBLA) seeking the approval of idecabtagene vicleucel (ide-cel; Abecma) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.1 The FDA has assigned…

Continue Reading FDA Accepts sBLA for Ide-cel in Triple-class Exposed Relapsed/Refractory Myeloma

120+ Active Companies working to develop 460+ Pipeline Therapies for CAR-T Treatment Landscape

PRESS RELEASE Published April 17, 2023 DelveInsight’s, “CAR-T Pipeline Insights 2023” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route…

Continue Reading 120+ Active Companies working to develop 460+ Pipeline Therapies for CAR-T Treatment Landscape

Bristol Myers Squibb – Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma

U.S. FDA accepted Bristol Myers Squibb and 2seventy bio’s supplemental Biologics License Application and has assigned a target action date of December 16, 2023 European Medicines Agency has validated Bristol Myers Squibb’s Type II variation application for Abecma Bristol Myers Squibb’s supplemental New Drug Application for Abecma has also been…

Continue Reading Bristol Myers Squibb – Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma

Caribou gets FDA fast track for allogeneic CAR-T

Caribou Biosciences is a biopharma company that has proprietary chRDNA (CRISPR hybrid RNA-DNA) technology, which allows for the creation of genome-edited cell therapies. One of the products of this technology, CB-011, was provided Fast Track designation by the US Food and Drug Administration (FDA). The treatment candidate is being evaluated…

Continue Reading Caribou gets FDA fast track for allogeneic CAR-T

300+ Leading Chimeric Antigen Receptor T-Cell Therapy Pipeline Companies are working to improve the Treatment Landscape | Major Companies

PRESS RELEASE Published March 27, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor T-Cell…

Continue Reading 300+ Leading Chimeric Antigen Receptor T-Cell Therapy Pipeline Companies are working to improve the Treatment Landscape | Major Companies

CAR-T Pipeline Analysis Demonstrates Novel 120+ Companies at the Horizon Expected to Transform the Treatment Paradigm

PRESS RELEASE Published March 15, 2023 DelveInsight’s, “CAR-T Pipeline Insights 2023,” report provides comprehensive insights about 120+ companies and 460+ pipeline drugs in the CAR-T pipeline landscape. It covers the CAR-T pipeline drug profiles, including CAR-T clinical trial and nonclinical stage products. It also covers the CAR-T pipeline therapeutics assessment…

Continue Reading CAR-T Pipeline Analysis Demonstrates Novel 120+ Companies at the Horizon Expected to Transform the Treatment Paradigm

Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…

Continue Reading Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

2023-02-10 | NYSE:BMY | Press Release

Abecma more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma Safety results were consistent with the well-established and predictable safety profile of Abecma Abecma is the first and only CAR T cell therapy to demonstrate superiority over standard regimens in…

Continue Reading 2023-02-10 | NYSE:BMY | Press Release

Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study

Abecma more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma Safety results were consistent with the well-established and predictable safety profile of Abecma Abecma is the first and only CAR T cell therapy to demonstrate superiority over standard regimens in…

Continue Reading Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study

Celyad Oncology Provides Fourth Quarter 2022 Business Update and 2023 Outlook

MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today provides a fourth quarter 2022 business update and an outlook for 2023. Michel Lussier, interim Chief Executive Officer…

Continue Reading Celyad Oncology Provides Fourth Quarter 2022 Business Update and 2023 Outlook

300+ Leading Chimeric Antigen Receptor T-Cell Therapy Pipeline Companies are working to improve the Treatment Landscape

PRESS RELEASE Published February 2, 2023 The “Chimeric Antigen Receptor T-Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in Chimeric Antigen Receptor T-Cell Therapy pipeline landscape. It covers the Chimeric Antigen Receptor T-Cell Therapy pipeline drug profiles, including Chimeric Antigen Receptor T-Cell…

Continue Reading 300+ Leading Chimeric Antigen Receptor T-Cell Therapy Pipeline Companies are working to improve the Treatment Landscape

Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the ‘Company’), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced an update on its financial results and recent business developments for the first half ended June…

Continue Reading Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Celyad Oncology Presents Updates on shRNA-Based CAR T

Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programs Management to host conference call today December 13th at 2:30 p.m. CET / 8:30 a.m. EST MONT-SAINT-GUIBERT, Belgium, Dec. 13, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext &…

Continue Reading Celyad Oncology Presents Updates on shRNA-Based CAR T

CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model

This article was originally published here Cancer Gene Ther. 2021 Sep 1. doi: 10.1038/s41417-021-00365-x. Online ahead of print. ABSTRACT The highly restricted expression of B-cell maturation antigen (BCMA) on plasma cells makes it an ideal target for chimeric antigen receptor (CAR) immune cell therapy against multiple myeloma (MM), a bone…

Continue Reading CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model

Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO | Rothwell, Figg, Ernst & Manbeck, P.C.

Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing biotech Verve raised $267M in IPO proceeds and later added another $40 million after its financial underwriters opted to buy…

Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO | Rothwell, Figg, Ernst & Manbeck, P.C.